Flp-In™ Complete System
Product Image
Invitrogen™

Flp-In™ Complete System

Nuestro sistema completo Flp-In™ permite la integración y expresión de su gen de interés en células de mamíferos en unaMás información
Have Questions?
Número de catálogoCantidad
K6010011 kit
Número de catálogo K601001
Precio (MXN)
-
Cantidad:
1 kit
Nuestro sistema completo Flp-In™ permite la integración y expresión de su gen de interés en células de mamíferos en una ubicación genómica específica. El sistema Flp-In implica la introducción de un sitio diana de recombinación FLP (FRT) en el genoma de la línea celular de mamíferos de elección. Un vector de expresión que contiene su gen de interés se integra en el genoma a través de la recombinación de ADN mediada por Flp recombinasa en el sitio de FRT.

Entre los principales componentes del sistema Flp-In™ se incluyen:

• Un vector del sitio diana Flp-In., pFRT⁄lacZeo, para la generación de la línea celular anfitriona que contiene el sitio de FRT integrado
• El plásmido de expresión que contiene un sitio TRF relacionado con el gen de resistencia a la higromicina para la integración y selección de una línea celular estable mediada por Flp recombinasa que expresa el gen de interés bajo control del potenciador⁄promotor del citomegalovirus (CMV) humano
• Plásmido de expresión de la Flp recombinasa, pOG44, para la expresión de la Flp recombinasa bajo el control del promotor CMV humano
• Plásmido de control de expresión que contiene el gen cloranfenicol acetil transferasa (CAT), que, cuando se cotransfecta con pOG44 en la línea celular anfitriona Flp-In., expresa CAT
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Sistema constitutivo o inducibleConstitutivo
Tipo de entregaTransfección
Para utilizar con (aplicación)Desarrollo de línea celular estable, integración orientada
Tipo de productoSistema completo Flp-In
Cantidad1 kit
Agente de selección (eucariótico)Zeocin™, higromicina
VectorpFRT
Método de clonaciónEnzimas de restricción/MCS
Línea de productosFlp-In, pcDNA
PromotorCMV
Etiqueta de proteínaSin etiquetar
Unit SizeEach
Contenido y almacenamiento
El sistema completo Flp-In™ incluye el kit básico (K601002), 1 g del antibiótico Zeocin™ y 1 g de higromicina B. Todos los vectores se suministran superenrollados y liofilizados. Almacenar la higromicina a +4 °C. Almacenar todos los demás componentes a -20 °C. El antibiótico Zeocin™ debe protegerse de la exposición a la luz. Se garantiza la estabilidad de todos los reactivos durante 6 meses si se almacenan correctamente.

Preguntas frecuentes

I performed the Flp-In reaction and obtained hygromycin-resistant clones which also turned out to be Zeocin antibiotic resistant and lacZ-positive. I am concerned that the Flp-In reaction has not worked. Can you explain what might be happening?

We have observed in-house that in cells where the FRT site has integrated into a very transcriptionally active locus in the host cell genome (seen more commonly in Flp-In CHO and Flp-In 293 cells but can also happen in Flp-In 3T3 cells and any other Flp-In host cell line), there is some "read-through" transcription and translation of the lacZ-Zeocin ORF subsequent to the Flp-In reaction, even though the lacZ-Zeocin ORF does not have a bonafide promoter and ATG. In such cases, the hygromycin-resistant clones would also be lacZ-positive and Zeocin antibiotic-resistant. To make sure that the integration is FRT site-specific and not random, we recommend doing a parallel control transfection with no pOG44 present. This should yield no surviving clones upon hygromycin selection, indicating that all the hygromycin-resistant clones obtained in the presence of pOG44 are indeed Flp recombinase-dependent and hence have the gene of interest integrated at the FRT site. Also, a Southern blot analysis of these clones will help verify that they do indeed have proper FRT integration of the gene of interest despite the expression of lacZ (although this is typically not necessary). After the Flp-In reaction, as long as you see hygromycin-resistant clones, we recommend that you select them and assay them for expression of your gene of interest.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I used the pcDNA5/FRT vector in your Flp-In 3T3 cell line and was initially able to express my gene of interest, but after a month or so, lost expression. Why is this?

The Flp-In 3T3 cell line is derived from NIH3T3 cells, which are mouse fibroblast cells. The CMV promoter is known to get silenced over time in murine cell lines and hence we would recommend using a Flp-In expression vector with a non-CMV promoter in these cells, such as the pEF5/FRT/V5-D-TOPO vector or the pEF5/FRT/V5-DEST vector.

I used the pFRT/lacZeo vector to generate my own Flp-In host cell line and then made my Flp-In expression cell line. I am seeing very poor expression of my gene of interest. Is there anything else I can try to improve expression?

Before giving up, we would suggest that you try using the pFRT/lacZeo2 vector to generate your host cell line. This vector contains a truncated version of the SV40 promoter driving the lacZ-Zeocin fusion. Use of this vector facilitates the isolation of clones that have integrated the vector near enhancer elements in the genome, thus resulting in higher levels of expression of the gene of interest.

What is the difference between the Jump-In and Flp-In systems?

The Jump-In system is PhiC31-integrase mediated and is a stable, targeted, and irreversible mammalian expression system. It consists of the Jump-In Fast system that involves a single integration step and the Jump-InTI (targeted integration) system that needs two integration steps, both of which are targeted and irreversible. In contrast, the Flp-In system is a stable, targeted mammalian expression system that is reversible. The first integration is random (integration of pFRT/lacZeo), and the second integration (integration of the Flp-In expression vector) is targeted but reversible.

Is multiple integration of the Flp-In expression construct possible? How do you screen for multiple integrants, and how stable is the Flp-In expression cell line?

In theory, one can get multiple integrations of the Flp-In expression construct—an FRT-specific integration event and a random, second-site integration. However, random integration is a relatively uncommon event. Limiting the amount of DNA in the transfection will reduce the chance of second-site integration. We have transfected 293 cells (lacking the FRT site) with the pcDNA5/FRT vector and have identified one potential second-site integrant after screening over 200 clones. DNA integrations can be detected by Southern blot. A single integrant will display a single band; double: two; triple: three, etc. We have maintained a number of Flp-In expression cell lines for over four months and have not observed any loss of the Flp-In expression construct, whether hygromycin selection was maintained or not.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Citations & References (15)

Citations & References
Abstract
Directed mutagenesis in region 713-720 of human thyroperoxidase assigns 713KFPED717 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies.
Authors:Bresson D, Pugnière M, Roquet F, Rebuffat SA, N-Guyen B, Cerutti M, Guo J, McLachlan SM, Rapoport B, Estienne V, Ruf J, Chardès T, Péraldi-Roux S,
Journal:J Biol Chem
PubMed ID:15150267
'Autoantibodies (aAbs) to thyroid peroxidase (TPO), the hallmark of autoimmune thyroid disease (AITD), recognize conformational epitopes restricted to an immunodominant region (IDR), divided into two overlapping domains A and B. Despite numerous efforts aimed at localizing the IDR and identifying aAb-interacting residues on TPO, only two critical amino acids, Lys(713) ... More
Does mPER2 protein oscillate without its coding mRNA cycling?: post-transcriptional regulation by cell clock.
Authors:Fujimoto Y, Yagita K, Okamura H,
Journal:Genes Cells
PubMed ID:16629904
'Does the mammalian oscillatory protein mPER2 show the rhythm without its coding mRNA cycling? Here we answer this question by inserting a single copy of exogenous mPer2 gene to a NIH3T3 fibroblasts cell line, using Flp-In system. We generated the stable cell lines which constantly express mRNAs coding either N-terminal ... More
Unlike Diablo/smac, Grim promotes global ubiquitination and specific degradation of X chromosome-linked inhibitor of apoptosis (XIAP) and neither cause apoptosis.
Authors:Silke J, Kratina T, Ekert PG, Pakusch M, Vaux DL,
Journal:J Biol Chem
PubMed ID:14570909
'Grim is a Drosophila inhibitor of apoptosis (IAP) antagonist that directly interferes with inhibition of caspases by IAPs. Expression of Grim, or removal of DIAP1, is sufficient to activate apoptosis in fly cells. Transient expression of Grim in mammalian cells induces apoptosis, arguing for the conservation of apoptotic pathways, but ... More
Genetic analysis of the herpes simplex virus type 1 UL20 protein domains involved in cytoplasmic virion envelopment and virus-induced cell fusion.
Authors:Melancon JM, Foster TP, Kousoulas KG,
Journal:J Virol
PubMed ID:15220406
'The herpes simplex virus type 1 UL20 protein (UL20p) is an important determinant for cytoplasmic virion morphogenesis and virus-induced cell fusion. To delineate the functional domains of the UL20 protein, we generated a panel of single and multiple (cluster) alanine substitutions as well as UL20p carboxyl-terminal truncations. The UL20 mutant ... More
Localization of the discontinuous immunodominant region recognized by human anti-thyroperoxidase autoantibodies in autoimmune thyroid diseases.
Authors:Bresson D, Cerutti M, Devauchelle G, Pugnière M, Roquet F, Bes C, Bossard C, Chardès T, Péraldi-Roux S,
Journal:J Biol Chem
PubMed ID:12501244
'The discontinuous immunodominant region (IDR) recognized by autoantibodies directed against the thyroperoxidase (TPO) molecule, a major autoantigen in autoimmune thyroid diseases, has not yet been completely localized. By using peptide phage-displayed technology, we identified three critical motifs, LXPEXD, QSYP, and EX(E/D)PPV, within selected mimotopes which interacted with the human recombinant ... More